濠电姷顣藉Σ鍛村磻閹捐泛绶ゅΔ锝呭暞閸嬪鏌eΟ娆惧殭鏉╂繈姊虹捄銊ユ珢闁瑰嚖鎷�
闂傚倸鍊风粈渚€骞栭锔藉亱闊洦绋戠粣妤呭箹濞n剙濡奸柛銊ュ€块弻銊╂偆閸屾稑顏�: 闂備浇顕уù鐑藉极婵犳艾纾诲┑鐘叉搐缁愭鏌¢崶鈺佹灁闁崇懓绉撮埞鎴︽偐閸欏鎮欏┑鈽嗗亝閿曘垽寮诲☉銏犖ㄩ柕蹇婂墲閻濇牠鎮峰⿰鍐ㄧ盎闁瑰嚖鎷� 闂傚倸鍊风欢姘缚閼姐倖瀚婚柣鏃傚帶缁€澶愬箹濞n剙濡奸柛姘秺楠炴牕菐椤掆偓閻忣噣鏌嶇紒妯荤闁哄被鍔戝顒勫垂椤旇瀵栨繝鐢靛仧閵嗗骞忛敓锟� 闂傚倷娴囧畷鍨叏瀹ュ绀冩い顓熷灣閻ヮ亪姊绘担鍛婃儓妞ゆ垵鍊垮畷婊冣攽閸垻鐓撴繝銏f硾婢跺洭宕戦幘缁樻櫜閹肩补鈧磭顔戠紓鍌欐缁躲倝骞忛敓锟� 闂傚倸鍊烽懗鑸电仚濡炪倖鍨甸崯鏉戠暦閺囥垺鐒肩€广儱鎳愰悾娲倵楠炲灝鍔氭い锔诲灣閻ヮ亣顦归柡灞剧〒娴狅箓鎮欓鍌涱吇缂傚倷鑳舵刊鎾箯閿燂拷 闂傚倸鍊烽懗鍫曘€佹繝鍕濞村吋娼欑壕鍧楁⒑椤掆偓缁夋挳宕归崒鐐寸厸闁告劑鍔庢晶娑㈡煟閹烘洦鍤欐い顓℃硶閹瑰嫰鎼归崷顓濈礃婵犵绱曢崕鎴﹀箯閿燂拷 闂傚倸鍊烽懗鍓佹兜閸洖鐤鹃柣鎰ゴ閺嬪秹鏌ㄥ┑鍡╂Ф闁逞屽厸缁舵艾鐣烽妸鈺佺骇闁瑰濯Σ娲⒑閼姐倕孝婵炲眰鍊曡灒濠电姴娲ょ粈澶愭煥閻曞倹瀚� 濠电姷鏁搁崑鐐哄垂閸洖绠伴悹鍥у斀缂傛碍绻涢崱妯虹伇濠殿喗濞婇弻鏇熷緞閸℃ɑ鐝旂紓浣插亾鐎光偓閸曨剙浠梺鎼炲劀閸曘劍鐏嗛梻浣告啞濡垿骞忛敓锟� 闂傚倸鍊峰ù鍥磻閹扮増鍋ら柡鍐ㄧ墕閸ㄥ倸霉閸忓吋鍎楅柡浣告閺屻劑鎮ら崒娑橆伓 闂傚倷娴囬褏鈧稈鏅犲畷妯荤節濮橆厸鎸冮梺鍛婃处閸撴岸宕h箛娑欑叆闁绘洖鍊圭€氾拷 濠电姷鏁搁崑鐐哄垂閸洖绠归柍鍝勬噹閸屻劑鏌i幘宕囩槏闁荤喐瀚堥弮鍫濆窛妞ゆ挾濯Σ娲⒑閼姐倕孝婵炲眰鍊曡灒濠电姴娲ょ粈澶愭煥閻曞倹瀚� 闂傚倸鍊风粈渚€骞夐敓鐘偓鍐疀濞戞ḿ锛涢梺绯曞墲缁嬫垿寮告笟鈧弻鐔煎箲閹伴潧娈紓浣哄У閸ㄥ潡寮婚敓鐘茬妞ゆ劧绲块々浼存⒑閸濄儱娅愰柟鍑ゆ嫹
濠电姷鏁搁崕鎴犲緤閽樺娲晜閻愵剙搴婇梺绋挎湰缁嬫捇銆呴悜鑺ョ叆闁绘洖鍊圭€氾拷: 闂傚倸鍊风粈渚€骞栭锕€纾归柣鎴f绾偓闂佸憡鍔曞Ο濠傘€掓繝姘叆闁绘洖鍊圭€氾拷 闂傚倷娴囧畷鍨叏閺夋嚚娲Χ閸ワ絽浜炬慨妯煎帶閻忥附銇勯姀锛勬噰闁轰焦鎹囬弫鎾绘晸閿燂拷 闂傚倷娴囧畷鐢稿窗閹扮増鍋¢柕澶堝剻濞戞ǚ妲堥柕蹇曞Х閿涙盯姊虹捄銊ユ珢闁瑰嚖鎷� 闂傚倷鐒﹂惇褰掑春閸曨垰鍨傞梺顒€绉甸崑銈夋煛閸ャ儱鐏柛搴★躬閺屻劑鎮ら崒娑橆伓 闂傚倸鍊烽悞锕傛儑瑜版帒纾归柡鍥╁枑濞呯娀鏌﹀Ο渚▓婵炲吋鐗犻弻銊╂偆閸屾稑顏� 闂傚倸鍊烽悞锕傛儑瑜版帒纾块柛妤冧紳濞差亜惟闁挎棁妫勫鍧楁⒑鐠恒劌娅愰柟鍑ゆ嫹 闂傚倸鍊烽懗鑸电仚缂備胶绮〃鍛存偩閻戣姤鍋ㄧ紒瀣閻庮剟姊虹捄銊ユ珢闁瑰嚖鎷� 闂傚倸鍊烽懗鍫曞磿閻㈢ǹ纾婚柟鎹愵嚙缁€澶愮叓閸ャ劍灏甸柡鍡愬€濋弻銊╂偆閸屾稑顏� 闂傚倸鍊烽懗鍫曘€佹繝鍕濞村吋娼欑壕瑙勪繆閵堝懏鍣圭紒鐘崇墵閺屻劑鎮ら崒娑橆伓 闂傚倸鍊峰ù鍥敋閺嶎厼绀傛繛鍡樻尭绾惧潡鏌$仦璇插姎闁汇倝绠栭弻銊╂偆閸屾稑顏� 闂傚倸鍊烽懗鑸电仚濡炪倖鍨甸崯鏉戠暦閺囥垹绠绘い鏃傜摂濡懘姊虹捄銊ユ珢闁瑰嚖鎷� 缂傚倸鍊搁崐鎼佸磹缁嬫5娲Χ閸♀晜顔旈梺褰掓?缁讹繝寮繝鍥ㄧ叆闁绘洖鍊圭€氾拷 濠电姷鏁搁崑鐐哄垂閸洖绠伴柛顐f礀绾惧綊鏌″搴″箹闁绘帒鐏氶妵鍕箳閹搭垱鏁鹃柣搴㈢啲閹凤拷 闂傚倸鍊烽懗鍫曞储瑜嶉锝夊箚閼割兛姹楅梺鍛婂姦閸犳牜绮堟径鎰叆闁绘洖鍊圭€氾拷 闂傚倸鍊烽悞锕€顪冮崹顕呯唵濞撴埃鍋撴鐐茬箻閺佹捇鏁撻敓锟� 濠电姷鏁告繛鈧繛浣冲洤纾诲┑鐘叉搐缁狀垶鏌ㄩ悤鍌涘 闂傚倸鍊烽懗鍫曞储瑜庨幆鏂库堪閸繄顔嗛梺璺ㄥ櫐閹凤拷 闂傚倷娴囬褏鎹㈤幇顓ф闊洦绋戠粻顖炴煥閻曞倹瀚� 闂傚倸鍊烽悞锕傚箖閸洖纾块柤纰卞墰閻瑩鏌熸潏鎯х槣闁轰礁妫濋弻銊╂偆閸屾稑顏� 闂傚倷娴囧畷鍨叏閺夋嚚娲煛娴g儤娈鹃梺鍓茬厛閸嬪懎鈻嶉悩缁樼叆闁绘洖鍊圭€氾拷 闂傚倸鍊风粈渚€骞栭鈷氭椽鏁冮埀顒€鐜婚崹顔规瀻闁规儳绉村ú顓㈠极閹剧粯鏅搁柨鐕傛嫹
濠电姷鏁搁崑鐐哄垂閸洖绠归柍鍝勬噹閸屻劑鏌ゅù瀣珒闁绘帒锕弻銊╂偆閸屾稑顏�: 闂傚倷鐒﹂惇褰掑春閸曨垰鍨傞梺顒€绉甸崑銈夋煛閸ャ儱鐏柛搴★躬閺屻劑鎮ら崒娑橆伓 闂傚倸鍊峰ù鍥ь浖閵娾晜鍊块柨鏇炲€归崑锟犳煥閺囨浜剧€光偓閿濆懏鍋ラ柡浣规崌閺佹捇鏁撻敓锟� 闂傚倸鍊峰ù鍥敋閺嶎厼绀堟慨妯块哺瀹曟煡鏌涢埄鍐槈闁绘帒鐏氶妵鍕箳閹搭垱鏁鹃柣搴㈢啲閹凤拷 濠电姷鏁搁崑鐐哄垂閸洖绠归柍鍝勬噹閻鏌嶈閸撴盯鍩€椤掑喚娼愰柟纰卞亰楠炲繘鏁撻敓锟� 闂傚倸鍊风粈渚€骞夐敓鐘冲亱闁绘劘灏欓弳锕傛煟閵忊懚鍦不閺嶎厽鐓ラ柣鏇炲€圭€氾拷 濠电姷鏁搁崑鐐哄垂閸洖绠伴悹鍥у斀缂傛碍绻涢崱妯虹伇濠殿喗濞婇弻銊╂偆閸屾稑顏� 闂傚倸鍊搁崐宄懊归崶顬盯宕熼娑樹罕闂佸湱鍋撳鍧楀极娓氣偓閺屻劑鎮ら崒娑橆伓 婵犵數濮甸鏍窗濡ゅ嫭鎳岄梻浣规偠閸斿繐鈻斿☉婊呬罕闂備浇娉曢崳锕傚箯閿燂拷 闂傚倸鍊风粈渚€骞栭锕€纾圭紒瀣紩濞差亜围闁搞儻绲芥禍鍓х棯閺夋妲归悗姘炬嫹 闂傚倸鍊烽悞锕傚垂濠靛鍊块柨鏇炲€告闂佺粯鍔楅弫鍝ョ矆婵犲洦鐓ラ柣鏇炲€圭€氾拷 濠电姴鐥夐弶搴撳亾濡や焦鍙忛柟缁㈠枛鐎氬銇勯幒鎴濐仼闁藉啰鍠栭弻銊╂偆閸屾稑顏� 闂傚倸鍊烽悞锕傚箖閸洖纾块柟缁樺笧閺嗭附淇婇娆掝劅婵炲皷鏅犻弻銊╂偆閸屾稑顏� 濠电姷顣槐鏇㈠磻濞戙埄鏁勯柛銉墮缁愭鏌熼幑鎰靛殭闁告垹濞€閺屻劑鎮ら崒娑橆伓 闂傚倸鍊峰ù鍥磻閹扮増鍋ら柡鍐ㄧ墕閸ㄥ倿鏌ц箛锝呬簼婵炲懐濞€閺屻劑鎮ら崒娑橆伓 闂傚倸鍊峰ù鍥磻閹扮増鍋ら柡鍐ㄧ墕閸ㄥ倹銇勯弽銊х煂缂佺姵妫冮弻銊╂偆閸屾稑顏� 闂傚倸鍊峰ù鍥磻閹扮増鍋ら柡鍐ㄧ墕閸ㄥ倿鏌熷▓鍨灓闁告宀搁弻銊╂偆閸屾稑顏� 闂傚倸鍊风粈渚€骞栭锕€纾归悷娆忓閸ㄦ棃鏌﹀Ο渚Ш闁哄棎鍊濋弻銊╂偆閸屾稑顏� 闂傚倸鍊烽懗鍫曞箠閹捐瑙﹂悗锝庡墮閸ㄦ繈骞栧ǎ顒€濡肩痪鎯с偢閺屻劑鎮ら崒娑橆伓 闂傚倸鍊风粈渚€宕ョ€n€綁骞掗幘鍙樼矒闂佸綊妫跨粈渚€宕欓悩缁樼叆闁绘洖鍊圭€氾拷
当前位置: 首页 > 期刊 > 《循环学杂志》 > 2003年第1期 > 正文
编号:10585955
Truncated Estrogen Receptor 46-kDa Isoform in Human Endothelial Cells

     From the Department of Cardiovascular Medicine, University of Oxford, UK.

    Abstract

    Background— Estrogen acutely activates endothelial nitric oxide synthase (eNOS). However, the identity of the receptors involved in this rapid response remains unclear.

    Methods and Results— We detected an estrogen receptor (ER transcript in human endothelial cells that encodes a truncated 46-kDa ER (1a-hER-46). A corresponding 46-kDa ER protein was identified in endothelial cell lysates. Transfection of cDNAs encoding the full-length ER (ER66) and 1a-hER-46 resulted in appropriately sized recombinant proteins identified by anti-ER antibodies. Confocal microscopy revealed that a proportion of both ER-66 and hER-46 was localized outside the nucleus and mediated specific cell-surface binding of estrogen as assessed by FITC-conjugated, BSA-estrogen binding studies. Both ER isoforms colocalized with eNOS and mediated acute activation of eNOS in response to estrogen stimulation. However, estrogen-stimulated transcriptional activation mediated by 1a-hER-46 was much less than with ER-66. Furthermore, 1a-hER-46 inhibited classical hER-66–mediated transcriptional activation in a dominant-negative fashion.

    Conclusions— These findings suggest that expression of an alternatively spliced, truncated ER{alpha} isoform in human endothelial cells confers a unique ability to mediate acute but not transcriptional responses to estrogen.

    Key Words: endothelium • cells • nitric oxide

    Introduction

    The classical actions of estrogen are mediated via interaction with nuclear steroid receptors leading to transcriptional regulation of various estrogen-responsive genes. However, recent evidence points to alternative pathways that mediate acute estrogen responses via cell-surface estrogen receptors (ERs).1–4 An important example is the rapid activation of endothelial nitric oxide synthase (eNOS)1,5 via a pathway involving mitogen-activated protein kinase and PI-3 kinase.5,6 However, the exact identity of the receptors involved in these nonclassical estrogen responses remains unclear.

    Some evidence suggests that a subpopulation of ER is localized within caveolae and can mediate acute eNOS activation.1 However, acute responses to estrogen in cell lines not expressing the classical ER (hER-66)7 and maintained vascular responses to estrogen in ER,8 ERß,9 and double ER knockout mice10 have led investigators to consider the possibility of other cell-surface ERs. Alternative ER{alpha} proteins encoded by mRNA splice variants are potential candidates for mediation of rapid estrogen responses, because there is no evidence for genes encoding ER homologues other than ERß.

    Human ER{alpha} mRNA isoforms are generated by splicing of 5 alternative upstream exons (B through F) to a common acceptor site 70 nucleotides (at +16311,12) upstream of the translation start site in exon 1. This alternative splicing produces identical-length proteins but raises the potential for differential, and hence tissue-specific, transcriptional regulation. In addition, an exon-1 truncated transcript (designated 1a-hER-46) has recently been demonstrated in a breast carcinoma cell line, resulting from splicing of the 5'UTR variant exon E or exon F directly to exon 2.13 In contrast to its full-length counterpart (hER-66), recombinant 1a-hER-46 has a predicted molecular weight of 46 kDa and lacks a transactivation domain, AF-1. This truncated ER acts as a competitive inhibitor of hER-66–mediated transactivation in some cell contexts.13 Furthermore, an ER-like protein of uncertain molecular identity, but similar size (45 kDa), was recently implicated in mediating acute estrogen responses in the EA.926 human endothelial cell line.7 We and others14 hypothesized that this protein could be translated from the 1a-hER-46 mRNA,13 suggesting a possible role for alternatively spliced ER transcripts in mediating acute estrogen responses.

    Accordingly, we sought to characterize the roles of the putative 1a-hER-46 and classical 66-kDa ER isoforms in mediating acute estrogen responses in human endothelial cells. In particular, we aimed to investigate the relative expression of these transcripts, their cellular localization, and their role in the acute activation of eNOS by estrogen in human endothelial cells.

    Methods

    Cell Culture

    Cell lines EA.926, hMEC, COS-1, and MCF-7 were propagated according to standard protocols. Human umbilical vein endothelial cells (HUVECs) were isolated from single donors and used at passages 2 through 4. For estrogen starvation, cells were incubated in medium without phenol red or serum.

    Reverse Transcriptase–Polymerase Chain Reaction

    RNA was obtained from human endothelial-derived cell lines and HUVECs with the use of Trizol reagent (Life Technologies). MCF-7 cells were used as a positive control. Reverse transcriptase (RT) was carried out by random priming with 1 µg of DNAase-treated RNA (Promega). Polymerase chain reaction (PCR) was performed with the use of forward primers based in 5' exons, as follows: 1A-F: 5'-GGAGCTGGCGGGGGGCGTTG-3'; 1BF: 5'- CGCGTTTAT-TTTAAGCCCAG- 3'; 1CF: 5'- CGGCCCTTGACTTCTACAAG-3'; 1DF: 5'-CTTCTTCACCTGAGAGAGCC-3'; 1EF: 5' CAG-AGAAATAATCGCAGAGC-3'; 1FF: 5'-CCAAAACTGA-AAATGCAGGC-3'. The reverse primer, located in exon 2, as follows, was common to all reactions: 2R: 5'-CCTTGCAG-CCCTCACAGGAC-3'.

    Construct Preparation

    The 1a-hER-46 pSG5 expression plasmid was generously provided by the Gannon laboratory (European Molecular Biology Laboratory, Heidelberg, Germany).13 hER{alpha} -66 pSG5 expression plasmid was created by subcloning the 5' coding sequence of ER (exons 1 through 4) from pEGFP-C1 hER (a gift from the Mancini laboratory, Baylor College of Medicine, Houston, Tex15) into pSG5-ER46 with the use of EcoRI and the HindIII site in exon 4.

    The fusion constructs 1a-hER-46-GFP and ER{alpha} -66-GFP were created by cloning from pSG5 into pEGFPN1 (Clontech Laboratories, Inc), with PCR used to generate an in-frame GFP fusion cDNA. The luciferase reporter gene (ERE)2-tk-Luc was a gift from the Scanlan laboratory (University of California, San Francisco).16 Plasmids were transfected into cells with Fugene 6 (Roche).

    Immunoblotting and Fluorescent Confocal Microscopy of ER{alpha} -Related Proteins

    Immunoblotting and immunofluorescence studies of ER-related protein were performed with monoclonal antibodies to ER{alpha} C-terminal (F-10, Santa Cruz Biotechnology). eNOS immunostaining (Transduction laboratories) was performed on COS cells cotransfected with an eNOS expression plasmid and GFP-tagged ER isoforms to examine the spatial relationships between eNOS and ER. Bound primary antibodies were visualized with TRITC-conjugated goat anti-mouse secondary antibodies (Sigma). Cells were imaged with a Biorad MRC 1024 confocal laser-scanning microscope.

    Determination of E2-Surface Binding With E2-Conjugated BSA-FITC

    Cells were transiently transfected with 1a-hER-46, hER-66, or ß-gal control plasmid. After 48 hours, cells were fixed and incubated in E2-conjugated BSA-FITC (Sigma) equating to 30 nmol/L of 17ß-estradiol. Unconjugated BSA-FITC was used to examine for nonspecific binding. Cells were mounted in Vectorshield (Vector Laboratories) containing DAPI and TO-PRO-3 and visualized by confocal microscopy.

    Determination of Estrogen-Induced eNOS Activation

    To visualize NO production, we loaded cells with diacetylated DAF-2 (DAF-2DA: Calbiochem). This membrane-permeable dye is hydrolyzed intracellularly by cytosolic esterases releasing DAF-2, which is converted in the presence of NO into a fluorescent product, DAF-2 triazole.17 Forty-eight hours after cotransfection with 1a-hER-46; ER-66 or control; and eNOS or control plasmids, COS cells were incubated in 1 µmol/L DAF-2DA solution for 30 mintes at 37°C in the dark and then washed. Cells were stimulated for 15 minutes in 17ß-estradiol (30 nmol/L) in the presence or absence of L-NMMA and then washed and fixed before examination under the confocal microscope.

    Estrogen-Dependent Transactivation in the Presence of 1a-hER-46

    The (ERE)2-tk-luc reporter gene construct was used to assess the effect of 1a-hER46 expression on the transcriptional activity of hER-66 in the human endothelial cell–derived hMEC and EA.926 cell lines and in COS cells. Cells were grown in 24-well plates and transfected at 24 hours with a total of 1 µg of DNA per well (0.25 µg of (ERE)2-tk-luc; 0.25 µg of 1a-hER46 expression vector or control expression vector; 0.25 µg of hER-66 expression vector or control expression vector; 0.25 µg of internal control ß-galactosidase expression vector). Cells were stimulated in 30 nmol/L 17ß-estradiol for 24 hours and then assayed for luciferase and ß-galactosidase activity. Reporter gene activity was normalized for transfection efficiency according to the activity of the cotransfected reference control.

    Results

    1a-hER46 Is Expressed in Human Endothelial Cells

    We first used RT-PCR to investigate the expression of ER transcripts in human endothelial cells. Both truncated (1a-hER-46) and full-length ER transcripts were present in human endothelial cells, including the EA.926 cell line, the hMEC microvascular endothelial cell line, and primary HUVEC cultures. In these cells, hER transcripts were derived exclusively from exons 1E and 1F. The smaller RT-PCR product observed in human endothelial cells was confirmed by sequencing to result from alternative mRNA splicing from 5' untranslated exons 1E or 1F directly to exon 2 ( in a manner previously described for the truncated 1a-hER-46 transcript in MCF-7 cells.13

    fig.ommitted

     A, RT-PCR demonstrating the expression of 1a-hER-46 transcript (lower bands) in human endothelial-derived cell lines EA.926, hMECs, HUVECs, and the positive control MCF-7 cells. The larger molecular weight bands seen are hER-66. The lower molecular weight products were confirmed by sequencing to result from a splice event from the 5' exons directly to exon 2 (B). 1a-hER-46 transcripts in the endothelial cells are derived from the 5' exons 1E and 1F. Forward primers for RT-PCR were based on sequence in 5' exons 1A through 1F, and the reverse primer based on sequence in exon 2 (common to all reactions) (B). The arrow points to the donor/acceptor site of 5' exon E/F and exon 2, respectively.

    Next, we sought to investigate whether appropriately sized ER proteins corresponding to these hER transcripts were present in endothelial cells. Western blots with an ER C-terminal antibody revealed only a 46-kDa ER protein in EA.926 cells in contrast to both 46- and 66-kDa ER proteins in MCF-7 cells This 46-kDa protein appeared of identical molecular weight to recombinant 1a-hER-46 expressed in COS cells after transient transfection of the respective cDNA . Although some hER-66 expression was detected by RT-PCR, repeated Western blots did not detect any ER protein corresponding to the 66-kDa full-length isoform, consistent with observations by the Bender laboratory.7

    fig.ommitted

     Western blot demonstrating a 46-kDA ER immunoreactive band in lysates of both MCF cells and EA.926 cells. This was the same molecular weight as that of the recombinant 1a-hER-46 isolated from transfected COS cells. The upper band seen in MCF-7 cells and COS cells transfected with ER-66 is the full-length ER isoform. No bands were identified in untransfected COS cells or in COS cells transfected with control ßgal plasmid.

    Subcellular Localization of hER{alpha} 46- and ER66-GFP Fusion Proteins

    We used ER-GFP constructs to investigate the subcellular localization of the 2 ER isoforms in transfected COS cells. The GFP was tagged to the C terminal, ensuring a similar position relative to both ER isoforms. Furthermore, the functional ability of the ER66-GFP fusion protein to mediate estrogen-dependent transactivation of a target sequence was confirmed before additional investigation. Most hER46- and hER-66-GFP fluorescence was observed within the nucleus. However, significant proportions of both recombinant hER-46 and hER-66 were observed outside the nucleus and in association with the plasma membrane Similar findings were observed in EA.926 cell and hMECs (data not shown). Nonpermeabilized, transfected cells immunostained for ER with C terminal antibody suggested cell-surface localization of a proportion of the receptor, as well as C terminal integrity of the ER component of the fusion proteins. Nontransfected COS cells or cells transfected with GFP-control vector were not recognized by the ER{alpha} antibody.

    fig.ommitted

     Cells transfected with GFP-tagged ERisoforms. Most of both conjugate proteins were located in the nucleus compared with the empty vector control (GFP). However, a significant proportion of both ER46- and ER66-GFP was extranuclear and associated with plasma membranes, as supported by the ER immunostaining (red, top panel) seen in nonpermeabilized COS cells transfected with ER46-GFP and ER66-GFP. ER-immunostaining was not observed in cells transfected with GFP-control plasmid. Secondary antibody controls were performed (bottom panel).

    We determined whether ER-GFP fusion proteins localized in the same way as ER itself. The distribution of fluorescence was similar to that observed in nontransfected human endothelial cell line EA.926 when stained with primary anti-ER antibody (data not shown), arguing against the observed distribution being a consequence of transfection or overexpression. The complete nuclear localization of hER-66 after prolonged exposure to physiological levels of estrogen additionally suggested that the observed extranuclear localization of the ER isoforms was not a result of the GFP disrupting nuclear localization signals (data not shown).

    hER-46 Associates With eNOS in Human Endothelial Cells

    To investigate the potential role of hER-46 in eNOS activation, we next investigated the association between hER-46 and eNOS proteins with the use of fluorescent confocal microscopy. In cells incubated without estrogen, a proportion of both hER-46 and hER-66 was observed to colocalize with eNOS . Colocalization with eNOS remained after 10 minutes of stimulation with 30 nmol/L 17ß-estradiol, but was lost after 24 hours of stimulation because of redistribution of ER to the nucleus (data not shown). These results demonstrate that hER-46 associates with eNOS in human endothelial cells in a similar manner to hER-66.

    fig.ommitted

     eNOS immunostaining on COS cells cotransfected with eNOS and GFP-tagged ER isoforms. The spatial relationship of these molecules was examined by fluorescent confocal microscopy. The confocal microscopy images demonstrate that a proportion of both 1a-hER-46 (ER46) and hER-66 (ER66) colocalizes with eNOS (yellow color indicated by white arrow) in the absence of estrogen stimulation.

    Cells Expressing ER{alpha} -46 and ER-66 Bind Estrogen at the Cell Surface

    Because we observed recombinant 1a-hER-46 at the cell membrane, we sought to investigate the ability of this protein to function as an estrogen receptor at this site. The cell-impermeable BSA-FITC tagged estradiol (E2coBSA-FITC: Sigma) was used to investigate estrogen binding at the surface of nonpermeabilized cells transfected with 1a-hER-46, hER{alpha} -66, or control (ß-gal) expression vectors. When transfected with the ß-gal control vector, nonpermeabilized cells did not bind the cell-impermeable E2coBSA-FITC compound. However, cells transfected with 1a-hER-46 or hER{alpha} -66 expression vectors bound E2coBSA-FITC at the cell surface at concentrations equivalent to 30 nmol/L 17ß-estradiol. Preincubation with unlabeled estradiol (3 µmol/L) abolished E2coBSA-binding, and the FITC-BSA control compound did not bind, showing ligand specificity. These results suggest that hER-46 functions as a specific estrogen-binding protein at the cell surface.

    fig.ommitted

     Nonpermeabilized COS cells transfected with 1a-hER-46 (ER46) or ER66 expression vectors contain surface binding sites for 17ß-estradiol (E2) detectable by cell-impermeant ligand binding (E2coBSA covalently linked to E2-FITC). Cells transfected with control plasmid (ßgal), or cells preincubated in unlabeled 17ß-estradiol (E2-FITC+E2) demonstrate no binding, as do cells exposed to BSA-FITC control compound. No background fluorescence was observed in control cells.

    ER-46 Mediates Estrogen-Induced eNOS Activation

    Having observed estrogen binding by hER-46 at the cell membrane and colocalization with eNOS, we next investigated its role in eNOS activation. Estrogen-induced eNOS activation was assessed in COS cells loaded with the NO-sensitive dye DAF-2DA. Confocal microscopy revealed that expression of 1a-hER-46 or hER-66 and eNOS resulted in estrogen-induced NO production not observed in the presence of either the ER isoforms or eNOS alone . NO production was antagonized by the eNOS inhibitor L-NMMA. The NO-sensitive DAF-fluorescence was observed in a punctate pattern both in association with the membrane and in the cytoplasm. These data indicate that estrogen-induced NO production in endothelial cells is mediated by functional associations between hER-46 or hER-66 and eNOS.

    fig.ommitted

    Estrogen-induced NO production in DAF-2DA–loaded, transfected COS cells. In the presence of NO, DAF-2 is converted into a fluorescent product, DAF-2 triazole, which can be visualized. Cells transfected with eNOS alone did not respond to acute estrogen stimulation. However, cells expressing both eNOS and either 1a-hER-46 (ER46) or ER66 demonstrated estrogen-induced eNOS activation (green fluorescence) that was inhibited by L-NMMA.

    ER-46 and ER-66 Mediate Differential Transcriptional Responses to Estrogen in Human Endothelial Cells

    Because both hER-46 and hER-66 mediate acute eNOS activation, we next compared their role in mediating classical, transcriptional responses after longer estrogen administration. Prolonged estradiol treatment at physiological levels (30 nmol/L for 24 hours) resulted in loss of membrane-associated GFP fluorescence and loss of GFP-eNOS colocalization (data not shown). In transient transfection experiments with the (ERE)2-tk-luc reporter gene construct, hER-66 mediated a marked transcriptional response to estrogen in hMECs, EA.926, and COS cell lines . In contrast, 1a-hER-46 mediated only a fraction of this reporter gene expression in these cell lines (P<0.001; n=3). Furthermore, coexpression of 1a-hER-46 and hER-66 reduced estrogen-induced transactivation compared with that mediated by hER-66 alone (P<0.01; n=3). These observations demonstrate that hER{alpha} -46 is a weak transcriptional activator compared with hER-66 and acts as a competitive inhibitor of hER-66–mediated transcriptional responses in these cells.

    fig.ommitted

     Transient transfection studies using the estrogen response element reporter plasmid (ERE)2-tk-LUC to examine the relative estrogen-dependent transcriptional activation mediated by 1a-hER-46 (ER46) compared with ER66. 1a-hER-46 has much less ability for estrogen-dependent transcriptional activity and inhibits that of ER66 in human endothelial cells. HMEC, EA.926, and COS cell lines were transfected with different combinations of a-hER-46 (hER46), hER66, or control expression vectors, as indicated. Cells were treated with or without estradiol (E2: 30 nmol/L) for 24 hours before being assayed for luciferase activity. Results are expressed as a percentage of the reporter gene activity measured from hER66 transfected cells stimulated with estrogen. Luciferase activities were normalized with the use of the internal reference control ß-galactosidase. + represents 0.25 µg of DNA used per 4 wells. In each case, the total quantity of DNA transfected was equalized with a control plasmid. Values correspond to the average±SEM of at least 3 separate transfection experiments, each performed in quadruplicate. P<0.05; P<0.01; P<0.001 compared with E2-induced transactivation mediated by hER66. Luciferase activity of control plasmids pGL3Basic (no promoter) and pGL3Control (containing SV40 promoter and enhancer) is provided for comparison.

    Discussion

    This study demonstrates expression of an exon 1–truncated hER isoform, hER-46, in human endothelial cells. This truncated ER localizes to the cell membrane, specifically binds E2, and mediates acute estrogen-induced eNOS activation. Because hER-46 mediates minimal estrogen-induced transcriptional activation and acts to competitively inhibit transcriptional activation by hER-66, these findings provide new evidence for differential receptor-mediated mechanisms underlying acute and transcriptional estrogen signaling in human endothelial cells.

    Despite the importance of estrogen-mediated effects in the vasculature, the identity of estrogen receptors that mediate acute effects of estrogen in endothelial cells has remained unclear. The classical ER-66 copurifies with and activates eNOS in isolated caveolae from ovine pulmonary arterial endothelial cells.1 However, our findings now suggest an important role for a novel splice variant of ERas an additional mediator of acute estrogen responses in human endothelial cells. Immunoidentification confirmed the predominance of the 46-kDa protein in EA.926 cells, the identical molecular weight of the recombinant 1a-hER-46. Primary HUVECs also express a 46-kDa ER{alpha} variant.7

    Use of hER-46 and hER{alpha} -66 GFP fusion proteins enabled us to determine the localization of these hER isoforms in living cells in relation to eNOS. The peripheral and membrane-associated localization of hER-46 and the partial colocalization with eNOS demonstrated by the hER46-GFP fusion protein was indistinguishable from that of hER-66, previously shown by ultracentrifugation and immunofluorescence studies to localize to plasma membrane caveolae.1

    We used a non–GFP tagged 1a-hER-46 expression vector to examine for the role of this truncated ER{alpha} isoform in acute and transcriptional responses to estrogen. Nontransfected COS cells posses no ER immunoreactivity and no transcriptional or acute response to estrogen. However, COS cells expressing 1a-hER-46 bound estrogen at the cell surface and demonstrated acute eNOS activation in response to estrogen in a similar manner to those expressing ER-66. Furthermore, these findings clarify previous observations in EA.926 cells, in which only a 45-kDa ER-like protein was detected, despite intact acute responses to estrogen.7 Our demonstration of 1a-hER-46 expression in several other human endothelial cell types now suggests that the exon 1 truncated ER isoform plays important roles in endothelial estrogen signaling.

    Specific binding of BSA-estradiol conjugates to the surface of cells expressing ER{alpha} -66 or 1a-hER46 is additional evidence supporting the ability of both isoforms to function as estrogen receptors in the mediation of acute, surface-related effects. A concern with the use of BSA-estradiol compounds is the possibility of incomplete conjugation that allows binding of free estradiol.18 However, this is only a limitation in studies addressing the acute physiological effects of BSA-estradiol administration. In our binding studies, any unconjugated estrogen would decrease the FITC signal seen at the cell surface by direct competition, as shown by addition of excess unconjugated estradiol. We used multiple additional controls, including BSA-FITC, together suggesting that membrane binding in cells expressing ER isoforms is estrogen-specific.

    The expression of hER in endothelial cells has important implications for acute versus transcriptional effects of estrogen signaling. Because hER-46 is only a weak mediator of transcriptional responses to estrogen and acts to inhibit the strong transcriptional activation mediated by hER66, the predominant expression of hER46 in endothelial cells would shift the balance of estrogen signaling toward acute rather than transcriptional responses. Differential expression of alternatively spliced ER variants may therefore provide a novel mechanism for modulation of estrogen responses in the vascular endothelium.

    Our identification of ER{alpha} 46 as an important mediator of acute estrogen effects in human endothelial cells highlights the importance of recent findings in ER{alpha} knockout mouse models. Alternative ER transcripts in the mouse, corresponding to human 1a-hER-46, may explain residual estrogen responsiveness in ER knockout mice (ERKO), in which only the first coding exon was targeted for disruption.19 In these mice, a short ER transcript is expressed that encodes an N-terminal truncated, mutant ER that binds estrogen but possesses significantly reduced estrogen-dependent transcriptional activity compared with that of the wild-type ER,20 resulting in the same functional domain changes as our findings with ER-46 in human endothelial cells. Indeed, the vascular responses to estrogen that are preserved in these ERKO mice8 are abolished in a new knockout mouse with total deletion of ER gene.21–23 Specifically, expression of alternatively spliced transcripts lacking the AF-1 domain in ERKO mice seems to mediate estrogen-induced endothelial NO production that is absent in the complete knockout.24 These insights from mouse models suggest that mouse homologs of 1a-hER-46 are sufficient to mediate the acute endothelial effects of estrogen and in principle support our observations of the functional effects of hER-46 in human endothelial cells, although the 46-kDa truncated ER protein was not readily detected in mouse aortic lysates.24 Additional studies are required to investigate possible roles for truncated ERs in mediating acute and transcriptional effects of estrogen in human pathophysiology.

    In conclusion, this study identifies a novel, exon 1–spliced ER{alpha} in human endothelial cells. The exon 1 truncated ER{alpha} is similar to ER-66 in its subcellular localization and ability to mediate estrogen binding at the surface of the membrane in ligand-specific fashion, leading to estrogen-induced eNOS activation. However, its inability to mediate transcriptional responses in endothelial cells suggests a unique role of this truncated ER in mediating differential acute versus transcriptional responses to estrogen in the vascular endothelium.

    Acknowledgments

    This work was supported by grants from the British Heart Foundation and from the Wellcome Trust. Dr Figtree was supported by the Rhodes Trust and by Trinity College, University of Oxford.

    Received June 21, 2002; revision received August 28, 2002; accepted September 13, 2002.

    References

    Chambliss KL, Yuhanna IS, Mineo C, et al. Estrogen receptor alpha and endothelial nitric oxide synthase are organized into a functional signaling module in caveolae. Circ Res. 2000; 87: E44–E52.

    Chen Z, Yuhanna IS, Galcheva-Gargova Z, et al. Estrogen receptor {alpha} mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest. 1999; 103: 401–406.

    Stefano GB, Prevot V, Beauvillain JC, et al. Cell-surface estrogen receptors mediate calcium-dependent nitric oxide release in human endothelia. Circulation. 2000; 101: 1594–1597.

    Kim HP, Lee JY, Jeong JK, et al. Nongenomic stimulation of nitric oxide release by estrogen is mediated by estrogen receptor alpha localized in caveolae. Biochem Biophys Res Commun. 1999; 263: 257–262.

    Haynes MP, Sinha D, Russell KS, et al. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res. 2000; 87: 677–682.

    Simoncini T, Hafezi-Moghadam A, Brazil DP, et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature. 2000; 407: 538–541.

    Russell KS, Haynes MP, Sinha D, et al. Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc Natl Acad Sci U S A. 2000; 97: 5930–5935.

    Iafrati MD, Karas RH, Aronovitz M, et al. Estrogen inhibits the vascular injury response in estrogen receptor {alpha} -deficient mice. Nat Med. 1997; 3: 545–548.

    Karas RH, Hodgin JB, Kwoun M, et al. Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc Natl Acad Sci U S A. 1999; 96: 15133–15136.

    Karas RH, Schulten H, Pare G, et al. Effects of estrogen on the vascular injury response in estrogen receptor {alpha} , ß (double) knockout mice. Circ Res. 2001; 89: 534–539.

    Green S, Walter P, Kumar V, et al. Human oestrogen receptor cDNA: sequence, expression and homology to v- erb-A. Nature. 1986; 320: 134–139.

    Flouriot G, Griffin C, Kenealy M, et al. Differentially expressed messenger RNA isoforms of the human estrogen receptor-alpha gene are generated by alternative splicing and promoter usage. Mol Endocrinol. 1998; 12: 1939–1954.

    Flouriot G, Brand H, Denger S, et al. Identification of a new isoform of the human estrogen receptor-{alpha} (hER-{alpha} ) that is encoded by distinct transcripts and that is able to repress hER-{alpha} activation function 1. EMBO J. 2000; 19: 4688–4700.

    Mendelsohn ME. Nongenomic, ER-mediated activation of endothelial nitric oxide synthase: how does it work? What does it mean? Circ Res. 2000; 87: 956–960.

    Stenoien DL, Mancini MG, Patel K, et al. Subnuclear trafficking of estrogen receptor-{alpha} and steroid receptor coactivator-1. Mol Endocrinol. 2000; 14: 518–534.

    Paech K, Webb P, Kuiper GG, et al. Differential ligand activation of estrogen receptors ER{alpha} and ERß at AP1 sites. Science. 1997; 277: 1508–1510.

    Kojima H, Nakatsubo N, Kikuchi K, et al. Detection and imaging of nitric oxide with novel fluorescent indicators: diaminofluoresceins. Anal Chem. 1998; 70: 2446–2453.

    Stevis PE, Deecher DC, Suhadolnik L, et al. Differential effects of estradiol and estradiol-BSA conjugates. Endocrinology. 1999; 140: 5455–5458.

    Lubahn DB, Moyer JS, Golding TS, et al. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci U S A. 1993; 90: 11162–11166.

    Couse JF, Curtis SW, Washburn TF, et al. Analysis of transcription and estrogen insensitivity in the female mouse after targeted disruption of the estrogen receptor gene. Mol Endocrinol. 1995; 9: 1441–1454.

    Dupont S, Krust A, Gansmuller A, et al. Effect of single and compound knockouts of estrogen receptors {alpha} (ER{alpha} ) and ß (ERß) on mouse reproductive phenotypes. Development. 2000; 127: 4277–4291.

    Pare G, Krust A, Karas RH, et al. Estrogen receptor- mediates the protective effects of estrogen against vascular injury. Circ Res. 2002; 90: 1087–1092.

    Brouchet L, Krust A, Dupont S, et al. Estradiol accelerates reendothelialization in mouse carotid artery through estrogen receptor-{alpha} but not estrogen receptor-ß. Circulation. 2001; 103: 423–428.

    Pendaries C, Darblade B, Rochaix P, et al. The AF-1 activation-function of ER{alpha} may be dispensable to mediate the effect of estradiol on endothelial NO production in mice. Proc Natl Acad Sci U S A. 2002; 99: 2205–2210.(Gemma A. Figtree MD DPhil Denise McDonald PhD Hugh Watkins MD PhD FRCP Keith M. Channon MD MRCP)
    濞e洠鍓濇导鍛閸涱剛杩旈柛娆忓€介埀顒€鍠涚槐婵囩▔瀹ュ棛鈧垶骞嬮幇顏呭床濞达絾娲戠粻锝咁嚈妤︽鍞撮柕鍡曠劍鐢綊鎳¢幇顓炵仐闁圭ǹ娲ょ槐鈺呭Υ閸屾稒鐎紒鏃傚Х婢ф寮堕崘銊ф剑濞存粌楠哥敮顐︽媼濡炲墽绋婇柡澶婂暕濮瑰鏁嶅畝鍐仧闁诡喓鍔忛缁樼▔閻戞﹩鍔冮柡鍌氭矗缁楀鈧绮忛~锕傚绩鐠鸿櫣绉垮〒姘☉閵囧洨鈧娉涢崢銈囨嫻瑜版帗顫夐悹鍥︾串缁辨繄鎷犻悜钘変粡濞寸姾鍩栭崹銊╂偨娴e啰妯堥梺顐f皑閻擄繝骞嬮幋婊勭拨闁挎稑鏈崹婊勭椤掍焦鏆柛鎺嶅嵆閳ь剚姘ㄩ悡锟犲触鎼搭垳绀夊ù鍏兼皑閻濇盯宕¢崘鑼闁诡喓鍔庡▓鎴炴媴濠婂啯鎯傚ù鐘插濠€鎵磾閹寸姷褰查柛鎺斿█濞呭酣濡撮敓锟�

   鐎甸偊鍠曟穱濠囧棘閸モ晝褰�  闁稿繗娅曢弫鐐烘儌閻愵剙顎�  閻犲洤瀚鎴﹀礄閻樻彃缍�  闁瑰吋绮庨崒銊╁即閺夋埈妯�   闁规亽鍔岄悺銊х磼濞嗘劖绠欓柛娆欐嫹   闁告梻濮撮崣鍡涘绩閹増顥�